Projected incidences based on changing demographics and average annual percentage change in incidence rates
| . | Men . | Women . | All . | ||
|---|---|---|---|---|---|
| Cancer sites . | AAPCa . | # of Casesb . | AAPCa . | # of Casesb . | # of Casesb . |
| All | |||||
| 2010 | −0.6 | 808,000 | NS | 761,000 | 1,569,000 |
| 2020 | 961,000 | 900,000 | 1,861,000 | ||
| 2030 | 1,086,000 | 1,049,000 | 2,135,000 | ||
| Bladder | |||||
| 2010 | NS | 57,000 | −0.4 | 19,000 | 76,000 |
| 2020 | 72,000 | 21,000 | 93,000 | ||
| 2030 | 89,000 | 24,000 | 113,000 | ||
| Breast | |||||
| 2010 | NS | 226,000 | 226,000 | ||
| 2020 | 262,000 | 262,000 | |||
| 2030 | 294,000 | 294,000 | |||
| Colon and rectum | |||||
| 2010 | −3.3 | 72,000 | −3.0 | 68,000 | 139,000 |
| 2020 | 65,000 | 61,000 | 127,000 | ||
| 2030 | 58,000 | 56,000 | 114,000 | ||
| Kidney and renal pelvis | |||||
| 2010 | NS | 30,000 | NS | 18,000 | 48,000 |
| 2020 | 37,000 | 22,000 | 59,000 | ||
| 2030 | 44,000 | 25,000 | 69,000 | ||
| Leukemia | |||||
| 2010 | 0.4 | 27,000 | 0.6 | 20,000 | 46,000 |
| 2020 | 33,000 | 24,000 | 57,000 | ||
| 2030 | 42,000 | 30,000 | 73,000 | ||
| Liver and intrahepatic bile | |||||
| 2010 | 3.7 | 19,000 | 2.9 | 7,000 | 26,000 |
| 2020 | 34,000 | 13,000 | 47,000 | ||
| 2030 | 62,000 | 21,000 | 83,000 | ||
| Lung and bronchus | |||||
| 2010 | −1.9 | 107,000 | −1.2 | 95,000 | 202,000 |
| 2020 | 115,000 | 104,000 | 219,000 | ||
| 2030 | 116,000 | 109,000 | 225,000 | ||
| Melanoma | |||||
| 2010 | 2.4 | 47,000 | 1.7 | 32,000 | 79,000 |
| 2020 | 70,000 | 41,000 | 111,000 | ||
| 2030 | 98,000 | 53,000 | 151,000 | ||
| Non-Hodgkin lymphoma | |||||
| 2010 | 0.7 | 38,000 | NS | 31,000 | 69,000 |
| 2020 | 49,000 | 37,000 | 86,000 | ||
| 2030 | 64,000 | 44,000 | 108,000 | ||
| Oral cavity and pharynx | |||||
| 2010 | NS | 25,000 | −0.9 | 10,000 | 35,000 |
| 2020 | 30,000 | 11,000 | 41,000 | ||
| 2030 | 34,000 | 12,000 | 46,000 | ||
| Pancreas | |||||
| 2010 | 1.3 | 22,000 | 1.4 | 22,000 | 43,000 |
| 2020 | 31,000 | 31,000 | 62,000 | ||
| 2030 | 43,000 | 44,000 | 88,000 | ||
| Prostate | |||||
| 2010 | −2.0 | 218,000 | 218,000 | ||
| 2020 | 235,000 | 235,000 | |||
| 2030 | 228,000 | 228,000 | |||
| Thyroid | |||||
| 2010 | 5.4 | 11,000 | 6.5 | 34,000 | 45,000 |
| 2020 | 21,000 | 71,000 | 92,000 | ||
| 2030 | 39,000 | 144,000 | 183,000 | ||
| Uterine corpus | |||||
| 2010 | 2.9 | 52,000 | 52,000 | ||
| 2020 | 82,000 | 82,000 | |||
| 2030 | 122,000 | 122,000 | |||
| . | Men . | Women . | All . | ||
|---|---|---|---|---|---|
| Cancer sites . | AAPCa . | # of Casesb . | AAPCa . | # of Casesb . | # of Casesb . |
| All | |||||
| 2010 | −0.6 | 808,000 | NS | 761,000 | 1,569,000 |
| 2020 | 961,000 | 900,000 | 1,861,000 | ||
| 2030 | 1,086,000 | 1,049,000 | 2,135,000 | ||
| Bladder | |||||
| 2010 | NS | 57,000 | −0.4 | 19,000 | 76,000 |
| 2020 | 72,000 | 21,000 | 93,000 | ||
| 2030 | 89,000 | 24,000 | 113,000 | ||
| Breast | |||||
| 2010 | NS | 226,000 | 226,000 | ||
| 2020 | 262,000 | 262,000 | |||
| 2030 | 294,000 | 294,000 | |||
| Colon and rectum | |||||
| 2010 | −3.3 | 72,000 | −3.0 | 68,000 | 139,000 |
| 2020 | 65,000 | 61,000 | 127,000 | ||
| 2030 | 58,000 | 56,000 | 114,000 | ||
| Kidney and renal pelvis | |||||
| 2010 | NS | 30,000 | NS | 18,000 | 48,000 |
| 2020 | 37,000 | 22,000 | 59,000 | ||
| 2030 | 44,000 | 25,000 | 69,000 | ||
| Leukemia | |||||
| 2010 | 0.4 | 27,000 | 0.6 | 20,000 | 46,000 |
| 2020 | 33,000 | 24,000 | 57,000 | ||
| 2030 | 42,000 | 30,000 | 73,000 | ||
| Liver and intrahepatic bile | |||||
| 2010 | 3.7 | 19,000 | 2.9 | 7,000 | 26,000 |
| 2020 | 34,000 | 13,000 | 47,000 | ||
| 2030 | 62,000 | 21,000 | 83,000 | ||
| Lung and bronchus | |||||
| 2010 | −1.9 | 107,000 | −1.2 | 95,000 | 202,000 |
| 2020 | 115,000 | 104,000 | 219,000 | ||
| 2030 | 116,000 | 109,000 | 225,000 | ||
| Melanoma | |||||
| 2010 | 2.4 | 47,000 | 1.7 | 32,000 | 79,000 |
| 2020 | 70,000 | 41,000 | 111,000 | ||
| 2030 | 98,000 | 53,000 | 151,000 | ||
| Non-Hodgkin lymphoma | |||||
| 2010 | 0.7 | 38,000 | NS | 31,000 | 69,000 |
| 2020 | 49,000 | 37,000 | 86,000 | ||
| 2030 | 64,000 | 44,000 | 108,000 | ||
| Oral cavity and pharynx | |||||
| 2010 | NS | 25,000 | −0.9 | 10,000 | 35,000 |
| 2020 | 30,000 | 11,000 | 41,000 | ||
| 2030 | 34,000 | 12,000 | 46,000 | ||
| Pancreas | |||||
| 2010 | 1.3 | 22,000 | 1.4 | 22,000 | 43,000 |
| 2020 | 31,000 | 31,000 | 62,000 | ||
| 2030 | 43,000 | 44,000 | 88,000 | ||
| Prostate | |||||
| 2010 | −2.0 | 218,000 | 218,000 | ||
| 2020 | 235,000 | 235,000 | |||
| 2030 | 228,000 | 228,000 | |||
| Thyroid | |||||
| 2010 | 5.4 | 11,000 | 6.5 | 34,000 | 45,000 |
| 2020 | 21,000 | 71,000 | 92,000 | ||
| 2030 | 39,000 | 144,000 | 183,000 | ||
| Uterine corpus | |||||
| 2010 | 2.9 | 52,000 | 52,000 | ||
| 2020 | 82,000 | 82,000 | |||
| 2030 | 122,000 | 122,000 | |||
Abbreviation: NS, nonsignificant.
aEdwards et al., (ref. 5, Table 1).
bAll projections for 2010 were calculated using rounded incidences from Smith et al. (3), and projections for 2020 and 2030 were calculated using the previous unrounded incidence projections, then rounded to the nearest 1,000.